PrEP: Challenges, Solutions, and Equitable Access

Kimberly Scott^*
*Correspondence: Kimberly Scott, Department of HIV Prevention and Care, University of California, San Francisco, San Francisco 94143,, United States, Email:

Introduction

Pre-exposure prophylaxis (PrEP) represents a pivotal strategy in the global effort to prevent HIV, offering a highly effective means of protection. However, achieving widespread and equitable access, alongside consistent uptake and adherence, remains a complex challenge, necessitating a nuanced understanding of various influencing factors. This introductory overview synthesizes recent findings regarding PrEP implementation, addressing diverse populations, delivery mechanisms, emerging interventions, and persistent societal barriers. One significant area of focus revolves around the experiences of women and girls in Sub-Saharan Africa, where PrEP uptake and adherence continue to present considerable hurdles, despite the proven efficacy of the intervention. What this really means is that we need to find better ways to support these groups to fully benefit from PrEP's protective power [1].

Here's the thing: implementing PrEP effectively in places with limited resources is tough. Reviews have identified key factors that help or hinder its rollout, emphasizing that community engagement, simplified delivery models, and addressing structural barriers are crucial for getting PrEP to those who need it most in these settings [2].

When it comes to young people and PrEP, both barriers and facilitators shape how they engage with it. Common hurdles like lack of awareness, stigma, and access issues exist alongside enablers such as youth-friendly services and supportive providers. This highlights the need for tailored approaches to reach and keep young individuals on PrEP [4].

Stigma continues to be a major hurdle for PrEP, affecting both uptake and consistent use. Fear of judgment, perceived stigma, and privacy concerns can deter individuals from seeking or staying on PrEP. Addressing these deeply rooted social issues is critical if we want to maximize PrEP's impact [6].

Looking at advancements in PrEP options, long-acting injectable cabotegravir is a game-changer, offering extended protection against HIV with fewer doses. This new formulation confirms high efficacy and a good safety profile, though it also points out practical challenges in integrating it into existing prevention programs. That means we need smart strategies to make it widely available and accessible [3].

Furthermore, flexibility in how PrEP services are delivered is crucial. Reviews focused on different ways PrEP services are delivered show that flexible models, like those integrating PrEP into existing health services or using telehealth, can significantly improve access and retention. The takeaway is that a 'one-size-fits-all' approach doesn't work; we need diverse strategies to meet varying community needs for PrEP [5].

Globally, PrEP scale-up is happening, which is great news, but this report highlights that uneven progress and persistent disparities remain. The big challenge is ensuring equitable access across different regions and populations, especially where HIV burden is highest. We're moving forward, but there's still a lot of work to do to reach everyone [7].

Economic considerations also play a vital role in PrEP implementation. Looking at the numbers, daily oral PrEP with TDF/FTC is indeed a cost-effective strategy for preventing HIV in the United States, providing strong economic evidence that investing in PrEP can save money in the long run by averting costly HIV infections and treatments. It's a smart public health investment [8].

Healthcare provider knowledge and attitudes are critical to PrEP access. Reviews revealed that while many providers support PrEP, significant gaps in knowledge and comfort discussing sexual health can limit its prescription. What this really means is we need better training and resources for healthcare professionals to become strong PrEP champions [9].

Finally, policy updates are essential for broader adoption. The CDC's updated guidelines for PrEP are a crucial step forward, reflecting the latest evidence and expanding recommendations for who should consider PrEP. This comprehensive review breaks down the key changes, emphasizing a broader eligibility and more flexible prescribing options, truly pushing for making PrEP a standard part of sexual health care [10].

Description

Pre-exposure prophylaxis (PrEP) is a cornerstone of current HIV prevention efforts, demonstrating high efficacy when consistently used. However, its real-world effectiveness is often hampered by significant barriers to uptake and adherence. For example, in Sub-Saharan Africa, women and girls continue to experience difficulties in engaging with PrEP, despite its clear benefits. This underscores a persistent need for context-specific interventions designed to support these vulnerable populations in fully realizing PrEPâ??s protective potential [1]. Parallel challenges exist in resource-limited settings globally, where the successful implementation of PrEP programs is frequently hindered by systemic and practical obstacles. Research indicates that effective rollout hinges on strong community engagement, the development of simplified delivery models, and proactive efforts to dismantle structural barriers that impede access for those who need it most [2]. Youth populations represent another key demographic facing unique hurdles in accessing and adhering to PrEP. Studies reveal common barriers such as a general lack of awareness, significant social stigma, and restricted access to services tailored for adolescents. Conversely, enablers like youth-friendly healthcare services and supportive providers can significantly improve engagement. This situation necessitates specialized, youth-centered strategies to effectively reach and maintain PrEP use among young individuals [4].

One of the most pervasive and challenging barriers to PrEP uptake and consistent use is stigma. This deeply rooted social issue manifests as fear of judgment, perceived societal disapproval, and privacy concerns, which collectively deter individuals from seeking PrEP or maintaining their regimen [6]. Addressing these complex social determinants is absolutely critical if global health initiatives aim to maximize the impact of PrEP as a prevention strategy. Until these underlying social issues are effectively managed, the full potential of PrEP will remain unrealized for many who could benefit.

Innovation in PrEP formulations and delivery methods offers promising avenues for overcoming existing challenges. The emergence of long-acting injectable cabotegravir, for instance, represents a significant advancement. This formulation provides extended protection against HIV with fewer doses, boasting high efficacy and a favorable safety profile [3]. Yet, its successful integration into existing HIV prevention programs presents practical hurdles that demand intelligent strategies for widespread availability and accessibility. What this really means is we must carefully plan how to incorporate this game-changing option into diverse healthcare infrastructures. Beyond new formulations, a flexible approach to service delivery is proving essential. Reviews of various PrEP service models demonstrate that differentiated approaches, such as integrating PrEP into existing primary care or sexual health services, or utilizing telehealth options, can markedly improve both access and retention rates [5]. This evidence strongly suggests that a 'one-size-fits-all' model is ineffective, emphasizing the need for diverse and adaptable strategies that can cater to the specific needs of varying communities.

Globally, efforts to scale up PrEP have been considerable, leading to notable progress in many regions. However, this progress is often uneven, characterized by persistent disparities in access and uptake [7]. The overarching challenge lies in ensuring truly equitable access across different geographical areas and population groups, especially within communities that bear the highest burden of HIV. While forward momentum is evident, significant work remains to achieve universal coverage. From an economic standpoint, the value of PrEP is clear. In the United States, daily oral PrEP with Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC) has been demonstrated to be a highly cost-effective strategy for HIV prevention [8]. The robust economic evidence indicates that upfront investment in PrEP can yield substantial long-term savings by averting costly HIV infections and subsequent treatment. It is, unequivocally, a smart public health investment that benefits both individuals and healthcare systems.

The role of healthcare providers is paramount in facilitating PrEP access and uptake. Unfortunately, significant gaps in provider knowledge and comfort levels when discussing sexual health often limit PrEP prescription, even among those who are generally supportive of the intervention [9]. What this really means is that enhanced training and resources are urgently needed to empower healthcare professionals to become confident PrEP champions, capable of initiating and maintaining conversations with eligible patients. Complementing these efforts, updated clinical guidelines provide crucial direction. The CDC's updated guidelines for PrEP represent a crucial step forward, integrating the latest scientific evidence and expanding recommendations for a broader range of individuals who should consider PrEP [10]. This comprehensive update emphasizes broader eligibility criteria and more flexible prescribing options, advocating for PrEP to become a standard, integrated component of routine sexual health care.

Conclusion

PrEP is a highly effective tool for HIV prevention, though its successful implementation is complex and multifaceted, requiring tailored approaches across diverse populations and settings. For instance, women and girls in Sub-Saharan Africa face distinct challenges with PrEP uptake and adherence, highlighting a critical need for specific interventions to ensure they fully benefit from its protective power. Similarly, in resource-limited settings, effective PrEP rollout is tough; community engagement, simplified delivery models, and addressing structural barriers are crucial for reaching those who need it most. The advent of long-acting injectable cabotegravir marks a significant advancement, offering extended protection with fewer doses and demonstrating high efficacy and a good safety profile. However, integrating this new option into existing prevention programs requires smart strategies for wide availability and accessibility. Young people also encounter unique barriers and facilitators influencing their engagement with PrEP, including lack of awareness, stigma, and access issues, underscoring the necessity for youth-friendly services and supportive providers. Stigma, alongside fear of judgment and privacy concerns, continues to be a major hurdle globally, deterring individuals from seeking or consistently using PrEP. Addressing these deeply rooted social issues is essential for maximizing PrEP's impact. Differentiated service delivery models, such as integrating PrEP into existing health services or using telehealth, have shown promise in improving access and retention, indicating that a one-size-fits-all approach is insufficient. Globally, while PrEP scale-up is progressing, uneven uptake and persistent disparities remain, particularly in regions with a high HIV burden, emphasizing the challenge of ensuring equitable access. Financially, daily oral PrEP with TDF/FTC is a cost-effective HIV prevention strategy in the United States, representing a smart public health investment. Finally, healthcare provider knowledge and attitudes significantly influence PrEP access; gaps in their understanding and comfort with sexual health discussions limit prescriptions, pointing to a need for better training. The CDC's updated guidelines further support expanding PrEP eligibility and making it a standard part of sexual health care.

Acknowledgement

None.

Conflict of Interest

None.

References

1. Naledi M, Lindiwe FS, Bvudzijena SC. "PrEP Uptake and Adherence in Women and Girls in Sub-Saharan Africa: A Systematic Review and Meta-Analysis".AIDS Behav 27 (2023):1-13.

Indexed at, Google Scholar, Crossref

2. Peninah MN, David PW, Margaret EH. "PrEP implementation in resource-limited settings: a scoping review of facilitators and barriers".BMC Public Health 22 (2022):863.

Indexed at, Google Scholar, Crossref

3. Raphael JL, Matthew RG, Huldrych FG. "Long-acting injectable cabotegravir for HIV pre-exposure prophylaxis: a review of efficacy, safety, and implementation".Lancet HIV 10 (2023):e413-e423.

Indexed at, Google Scholar, Crossref

4. Jessica MH, David WD, Kelly EB. "Barriers and Facilitators to Pre-Exposure Prophylaxis (PrEP) Uptake and Adherence among Young People: A Systematic Review".Curr HIV/AIDS Rep 18 (2021):191-203.

Indexed at, Google Scholar, Crossref

5. Kelly EB, Michele R, Kathryn MC. "Differentiated Service Delivery for HIV Pre-Exposure Prophylaxis (PrEP): A Systematic Review".Curr HIV/AIDS Rep 18 (2021):204-213.

Indexed at, Google Scholar, Crossref

6. Sarah CC, Andrea JE, Alana MB. "The Role of Stigma in PrEP Uptake and Adherence: A Systematic Review".AIDS Behav 25 (2021):1004-1022.

Indexed at, Google Scholar, Crossref

7. Rakesh LK, Kevin MP, Rachel SC. "Global Progress on HIV Pre-Exposure Prophylaxis (PrEP) Scale-Up and the Remaining Challenges".Curr HIV/AIDS Rep 20 (2023):231-240.

Indexed at, Google Scholar, Crossref

8. Joshua APS, Rochelle PW, Amy KG. "Cost-Effectiveness of Daily Oral Tenofovir Disoproxil Fumarate/Emtricitabine as Pre-Exposure Prophylaxis for HIV Prevention in the United States".Clin Infect Dis 68 (2019):1899-1907.

Indexed at, Google Scholar, Crossref

9. Laura AO, Amy EL, Kelly RB. "Healthcare provider attitudes and practices regarding HIV pre-exposure prophylaxis (PrEP): a systematic review".AIDS Care 33 (2021):190-202.

Indexed at, Google Scholar, Crossref

10. Kimberly JN, Jonathan GM, Rebecca JS. "CDC's Updated Clinical Practice Guideline for HIV Preexposure Prophylaxis: A Comprehensive Review".Clin Infect Dis 75 (2022):1989-1996.

Indexed at, Google Scholar, Crossref